Made Scientific Company Profile

Background

Made Scientific, formerly known as BioCentriq, is a leading cell therapy contract development and manufacturing organization (CDMO) dedicated to advancing the field of cell therapy. Established in 2019, the company specializes in developing, manufacturing, and releasing autologous and allogeneic cell therapy products for early- to mid-stage clinical trials. It has since evolved into an end-to-end clinical-to-commercial service provider. Operating from two U.S.-based manufacturing facilities, Made Scientific combines the flexibility and entrepreneurial spirit of a specialist CDMO with the global expertise and resources of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors.

Key Strategic Focus

Made Scientific's strategic focus centers on accelerating life-saving cell therapies from development to commercialization. The company emphasizes streamlining complex processes, reducing development timelines, and overcoming scientific and operational challenges to ensure that groundbreaking therapies reach patients efficiently. Its core objectives include:

Process and Analytical Development: Enhancing the efficiency and robustness of cell therapy processes.

GMP Cell Banking and Drug Product Manufacturing: Ensuring high-quality production standards.

GMP Aseptic Fill and Finish: Maintaining sterility and product integrity.

Quality Control Release Testing and Stability Studies: Guaranteeing product safety and efficacy.

Workforce Development and Training: Building a skilled workforce to support advanced therapies.

The company targets a broad spectrum of cell types, including T cells, NK cells, HSCs, MSCs, iPSCs, and TILs, catering to diverse therapeutic areas.

Financials and Funding

In January 2024, Made Scientific secured $29.2 million in Series A funding, bolstering its financial position and supporting its expansion initiatives. The capital is intended for facility upgrades, equipment procurement, and enhancement of business systems to strengthen the company's capabilities in the rapidly growing cell therapy sector.

Pipeline Development

As a CDMO, Made Scientific collaborates with various clients to develop and manufacture cell therapy products. While specific pipeline candidates are proprietary to their clients, the company's comprehensive suite of services supports the entire product lifecycle, from pre-clinical development through Phase I-III trials to commercial enablement.

Technological Platform and Innovation

Made Scientific distinguishes itself through its state-of-the-art facilities and advanced technological platforms:

Proprietary Technologies: The company utilizes cutting-edge analytical and manufacturing technologies, including advanced bioreactors and automated cell processing systems, to ensure scalable and efficient production.

Scientific Methodologies: Emphasizing quality-by-design principles, Made Scientific integrates data-driven approaches to transform promising therapies into reproducible manufacturing processes.

Leadership Team

Made Scientific's leadership comprises seasoned professionals with extensive experience in the biopharmaceutical industry:

Syed T. Husain, Chairman & CEO: Brings extensive expertise in CDMO development and manufacturing services, leading companies through rapid growth and market innovation.

Sun Ra Bullins, VP & Head of Technical Operations: Over two decades of biopharmaceutical operations expertise, specializing in GMP manufacturing and process optimization.

Chithkala (Ck) Harinarayan, VP & Head of Quality & Compliance: With more than 25 years in cell therapy and biologics, she fosters a culture where compliance and innovation work in harmony.

David Smith, Ph.D., VP & Head of Development: Oversees Manufacturing Science & Technology, Process Development, and Analytical Method Development with 15+ years of experience in regenerative medicine and cell therapy manufacturing.

Joseph Sinclair, VP & Head of Commercial: Directs commercial strategy and client partnerships, bringing over 15 years of experience in scaling CDMO operations for advanced therapeutics.

Adam Haskett, Sr. Director & Head of Strategic Alliances and Partnerships: Brings over 15 years of expertise in biologics and advanced therapies, enabling strategic partnerships that enhance cell therapy manufacturing capabilities.

Michelle Ng, Sr. Director & Head of Portfolio and Program Management: Over 13 years of project management experience, specializing in driving collaboration between clients and CDMOs.

Ria S. Barrett, Sr. Director & Head of Human Resources: Leads people-centered strategies with 15+ years of HR leadership across life sciences and professional services sectors.

Byungyong (Henry) Han, Sr. Director & Head of Finance: Guides financial strategy and operational efficiency with more than 15 years in financial management.

Leadership Changes

In September 2024, Syed T. Husain was appointed as Chief Executive Officer and member of the Board of Directors, bringing extensive expertise in CDMO development and manufacturing services.

Competitor Profile

Market Insights and Dynamics

The cell therapy CDMO market is experiencing significant growth, driven by advancements in regenerative medicine and increasing demand for personalized therapies. The market is characterized by rapid technological innovations, evolving regulatory landscapes, and a competitive environment where quality, scalability, and speed to market are critical differentiators.

Competitor Analysis

Key competitors in the cell therapy CDMO space include:

WuXi Advanced Therapies: Offers comprehensive services in cell and gene therapy development and manufacturing, emphasizing integrated platforms and global reach.

Lonza: Provides end-to-end solutions for cell and gene therapies, with extensive experience in process development and commercial manufacturing.

Catalent Pharma Solutions: Specializes in advanced delivery technologies and development solutions, including cell and gene therapy services.

These competitors focus on scalability, technological innovation, and regulatory compliance to meet the growing demands of the cell therapy market.

Strategic Collaborations and Partnerships

In January 2025, Made Scientific announced a strategic partnership with Orchestra Life Sciences, a premier technical consultancy firm specializing in advanced therapy manufacturing solutions. This collaboration aims to enhance manufacturing capabilities and deliver exceptional client value.

Operational Insights

Made Scientific's strategic considerations include:

Flexible Partnership Models: Offering traditional, hybrid client-in-plant operations, and custom build-outs to meet diverse client needs.

State-of-the-Art Facilities: Operating from two U.S.-based manufacturing facilities equipped with advanced technologies to support scalable and efficient production.

Comprehensive Service Offering: Providing end-to-end cell therapy development and manufacturing services to support clients throughout the product lifecycle.

Strategic Opportunities and Future Directions

Made Scientific's strategic roadmap includes:

Facility Expansion: Investing over $12 million in facility upgrades, equipment, and business system enhancements to strengthen capabilities in the cell therapy sector.